Corticodependency and corticoresistance in Crohn's disease: Prevalence and predictive factors;Corticodependance et corticoresistance au cours de la maladie de Crohn: Prevalence et facteurs predictifs

Tunisie Medicale

Volumn 81, Issue 1, 2003, Pages 15-19

  Karoui, Sami ^a   Yaghlene Ben, Lamia ^a   Fekih, Monia ^a   Boubaker, Jalel ^a   Filali, Azza ^a  

^a LA RABTA HOSPITAL   (Tunisia)

Author keywords

Corticosteroids; Crohn's disease

Indexed keywords

CORTICOSTEROID;

ADULT; ARTICLE; CROHN DISEASE; DISEASE ACTIVITY; DRUG DEPENDENCE; DRUG SENSITIVITY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; PREDICTION; PREVALENCE; TREATMENT OUTCOME;

ADRENAL CORTEX HORMONES; ADULT; CROHN DISEASE; DRUG RESISTANCE; FEMALE; HUMANS; MALE; PREVALENCE; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 0037256651     PISSN: 00414131     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Modigliani R, Mary JY, Simon JF, Cortot A, Soule JC, Gendre JP et al. Clinical, biological, and endoscopic picture of attacks of Crohn's disease. Evolution on prednisolone. Gastroenterology 1990;98:811-8.
2. Malchow H, Ewe K, Brandes JW, Goebell H, Ehms H, Sommer H et al. European-cooperative Crohn's disease study (ECCDS): results of drug treatment. Gastroenterology 1984;86:249-66.
3. Munkholm P, Longholz E, Davidsen M, Binder V. Frequency of glucorticoid resistance and dependency in Crohn's disease. Gut 1994;35:360-2.
4. Bamberger CM, Bamberger AM, de Castro M, Chrousos P. Glucocorticoid receptor b, a potential endogenous inhibitor of glucocorticoid action in humans. J Clin Invest 1995;95:2435-41.
5. Reinisch W, Gasché C, Wyatt J, Moser G, Lochs H, Vogelsang H et al. Steroid dependency in Crohn's disease. Lancet 1995;345:859.
6. Brignola C, De Simone G, Belloli C, Iannone P, Belluzzi A, Gionchetti P et al. Steroid treatment in active Crohn's disease: a comparison between two regimens of different duration. Aliment Pharmacol Ther 1994;9:465-8.
7. Summers RW, Switz DM, Sessions JT, Becktel JM, Best WR, Kern F et al. National Cooperative Crohn's Disease Study: results of drug treatment. Gastroenterology 1979;77:847-69.
8. Modigliani R, Les corticoïdes dans les maladies inflammatoires inflammatoires cryptogénétiques de l'intestin: mode d'emploi. Gastroenterol Clin Biol 1999;23:B169-B177.
9. Franchimont DP, Louis E, Cros F, Belaiche J. Clinical patterns of corticosteroid dependent Crohn's disease. Eur J Gastroenterol Hepatol 1998;10:821-5.
10. De Castro M, Elliot S, Kino T, Bamberger C, Karl M, Webster E et al. The nonligand beta-isoform of the human glucocorticoid receptor (hGRb): tissue levels, mechanism of action and potential physiologic role. Mol Med 1996;2:597-607.
11. Carbonnel F, Gargouri D, Lemann M, Beaugerie L, Cattan S, Cosnes J et al. Predictive factors of outcome of intensive intravenous treatment for attacks of ulcerative colitis. Aliment Pharmacol Ther 2000; 14:273-9.
12. Sandborn WJ. A review of immune modifier therapy for inflammatory bowel disease: Azathioprine, 6-Mercaptopurine, cyclosporine, and methotrexate. Am J Gastroenterology 1996;91:423-33.
13. Modigliani R, Colombel JF, Dupas JL, Dapoigny M, Costil V, Veyrac M et al. Mesalamine in Crohn's disease with steroid-induced remission: effect on steroid withdrawal and remission maintenance. Gastroenterology 1996;110:688-93.
14. Corlot A, Colombel JF, Rutgeerts P, Lauritsen K, Malchow H, Hämling J et al. Switch from systemic steroids to budesonide in steroid dependent patients with inactive Crohn's disease. Gut 2001;48:186-90.